nifedipine has been researched along with troglitazone in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (16.67) | 18.2507 |
2000's | 2 (11.11) | 29.6817 |
2010's | 13 (72.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mori, M; Ohtani, KI; Sato, N; Shimizu, H | 1 |
Hisatome, I; Ikeda, T; Ogino, K; Shimoyama, M; Tanaka, Y | 1 |
Asano, M; Hazama, H; Imuta, H; Iwasawa, K; Kawakami, Y; Morita, T; Nakajima, T; Nakamura, F; Okuda, Y; Omata, M; Oonuma, H; Suzuki, J; Suzuki, S | 1 |
Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
Chen, C; Gao, Y; Liu, D; Wang, H; Zhu, J | 1 |
1 review(s) available for nifedipine and troglitazone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for nifedipine and troglitazone
Article | Year |
---|---|
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells.
Topics: Animals; Calcium; Cell Division; Cells, Cultured; Chromans; Cricetinae; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Mesocricetus; Nifedipine; Thiazoles; Thiazolidinediones; Troglitazone | 1998 |
Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts.
Topics: Animals; Blood Pressure; Calcium Channels; Chromans; Coronary Circulation; Heart Rate; Hemodynamics; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Nifedipine; Nitroprusside; Prazosin; Propranolol; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Thiazoles; Thiazolidinediones; Troglitazone; Ventricular Function, Left | 1999 |
Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiotonic Agents; Chromans; Cyclic AMP; Electric Conductivity; Guinea Pigs; Hypoglycemic Agents; Isoproterenol; Kinetics; Myocardium; Nifedipine; Thiazoles; Thiazolidinediones; Troglitazone; Verapamil | 1999 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.
Topics: Aryl Hydrocarbon Hydroxylases; Chromans; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8; DNA Primers; Drug Discovery; Drug Interactions; Genetic Vectors; Humans; Isoenzymes; Kinetics; Microsomes; Nifedipine; Paclitaxel; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Regression Analysis; Saccharomyces cerevisiae; Thiazolidinediones; Troglitazone | 2010 |